Bhagirathbhai Dholaria, MBBS, on Administering Axi-Cel in the Outpatient Setting for LBCL

Video

The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings.

“Our analysis showed that yes, with appropriate safety guards and training and infrastructure, CAR T cell therapy, especially axi-cel, which has highest risk of cytokine release syndrome and neurotoxicity compared to other CD19-directed CAR T cell therapies such as tisa-cel and liso-cel, it can be still safely given.”

Clinicians from University of Vanderbilt investigated outcomes with remote monitoring patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel; Yescarta) and found that safety and efficacy outcomes were similar between patients treated in inpatient and outpatient settings. Data from the retrospective analysis were presented at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke with coauthor Bhagirathbhai Dholaria, MBBS, assistant professor of medicine at Vanderbilt University Medical Center, to learn more about the study and the favorable outcomes observed in patients treated in the outpatient setting. He discussed the advantages for both patients and hospitals with outpatient chimeric antigen receptor (CAR) T-cell therapy treatments.

For more coverage of the 2023 Tandem Meetings, click here.

REFERENCE
Akosile TA, Dholaria B, Baer B, et al. The impact of telemedicine and wearable devices in improving the safety profile of outpatient chimeric antigen receptor T-Cell (CAR-T) therapies: A case-control study. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida. Abstract #201
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.